The article examines the objective, findings, and clinical context described in FDA approves olanzapine injection for schizophrenia.
Approach:
Approval: The FDA approved Weltruza, a once-monthly subcutaneous long-acting olanzapine suspension for adults with schizophrenia. It does not require loading doses, oral supplementation, or routine post-injection monitoring.
Supporting trial: Approval was supported by SOLARIS, a multinational, randomized, double-blind, placebo-controlled phase 3 trial. In its initial 8-week period, 675 adults aged 18–64 received one of three monthly doses or placebo.
Key Findings:
All three doses met the primary endpoint of change in PANSS total score at week 8. Mean differences versus placebo were −9.69 points with 318 mg, −11.25 with 425 mg, and −9.71 with 531 mg.
Improvements in illness severity and personal and social functioning were also reported.
Weight gain occurred in 35% of olanzapine-treated patients and 8% of placebo recipients. Other commonly reported adverse events included somnolence, headache, constipation, and injection-site reactions.
Adverse event–related discontinuations occurred in 1%–3% of patients in both groups. No PDSS cases were reported through week 8 or among 3,470 injections through week 56; prescribing information states that whether PDSS can occur remains unknown.
Interpretation:
The three monthly strengths correspond to oral olanzapine doses of 10 mg, 15 mg, and 20 mg daily. Reported weight gain and metabolic abnormalities were consistent with oral olanzapine’s known safety profile.
Limitations:
The supplied trial results describe the initial 8-week placebo-controlled period; longer-term findings are limited here to the reported absence of PDSS cases through week 56.
The prescribing information states that whether PDSS can occur with olanzapine remains unknown.
Conclusion:
Olanzapine carries a boxed warning for increased mortality in older adults with dementia-related psychosis and is not approved for this population. Other listed risks include hyperglycemia, dyslipidemia, weight gain, neuroleptic malignant syndrome, tardive dyskinesia, orthostatic hypotension, and drug reaction with eosinophilia and systemic symptoms. Teva advises assessing metabolic risk before treatment and monitoring blood glucose and other metabolic parameters during therapy.
